48 filings
8-K
MAIA
MAIA Biotechnology Inc
6 Jun 24
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
2:57pm
8-K
MAIA
MAIA Biotechnology Inc
4 Jun 24
Regulation FD Disclosure
4:06pm
8-K
MAIA
MAIA Biotechnology Inc
3 Jun 24
Regulation FD Disclosure
4:05pm
8-K
MAIA
MAIA Biotechnology Inc
29 May 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
MAIA
MAIA Biotechnology Inc
15 May 24
Other Events
4:07pm
8-K
v1g6xbaoxw 456k32h2
7 May 24
Regulation FD Disclosure
5:21pm
8-K
iki010
23 Apr 24
MAIA Biotechnology Announces $1.00 Million Private Placement
4:05pm
8-K
af92wl6cj2azl6
2 Apr 24
Departure of Directors or Certain Officers
4:10pm
8-K
8x3wi32e
26 Mar 24
MAIA Biotechnology Announces $1.33 Million Private Placement
3:36pm
8-K
0bc5nyn
25 Mar 24
Other Events
4:08pm
8-K
hfo2c5o3
13 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
y5213ozjnx
8 Mar 24
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
4:15pm
8-K
k3sz7cdge
6 Mar 24
Other Events
8:00am
8-K
abgxg8
27 Feb 24
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
5:23pm
8-K
o0tg krf7
23 Feb 24
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
4:17pm
8-K
hybv8g857 atqpk6
14 Feb 24
Entry into a Material Definitive Agreement
5:15pm
8-K
aljt9nfnad4
30 Jan 24
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
9:00am
8-K
okdtjl
18 Jan 24
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
6:01am
8-K
5sz1augx7ooko
21 Dec 23
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
7:00am
8-K
bv6vus2e xhjcyo
17 Nov 23
MAIA Biotechnology Announces $4 Million Registered Direct Offering
9:09am